Target intelligence / Profile preview

TCDD-inducible poly(ADP-ribose) polymerase (TIPARP)

Target
TIPARP
Molecular classification
Enzyme, ADP-ribosyltransferase
01

Overview

TCDD-inducible poly(ADP-ribose) polymerase (TIPARP, also known as Poly(ADPr)-polymerase 7 or PARP7), is a member of the poly(ADPr)-polymerases (PARPs), a protein family involved in post-translational modification through ADPr transfer from NAD+ onto substrate proteins. Unlike canonical members such as PARP1 that catalyze formation of long branched polymers ("poly"-ribosylation), TIPARP primarily mediates mono ADPr transfer ("mono"-ribosylation). The biological functions attributed to this enzyme include regulation of gene expression via chromatin remodeling and modulation of cellular responses following exposure to environmental toxins such as dioxins. While much research has focused on other family members like PARP1/2 due to their central role in DNA repair pathways—and thus their value as cancer drug targets—emerging evidence suggests that selective inhibition or modulation of enzymes like TIPARP could have therapeutic potential but requires further study regarding specificity, efficacy, and safety profiles. Note: The submitted name "Poly polymerase 7" does not conform with accepted nomenclature; the correct designation should be TCDD-inducible poly(ADPr)-polymerase (TIPARP/PARP7).

Other names
PARP7TIPARPPoly(ADP-ribose) polymerase 7
02

Mechanism of action

For general PARPs: Inhibition leads to impaired DNA repair and synthetic lethality in cells with defective homologous recombination. For TIPARP: Likely involves inhibition of mono ADP-ribosylation activity on specific substrates.

03

Biological functions

Mono-ADP-ribosylation of target proteinsRegulation of transcription and chromatin structureModulation of cellular response to stress and DNA damage
04

Disease associations

Cancer
05

Safety considerations

Notable safety concerns have been described primarily with pan-PARPi targeting multiple family members—hematologic toxicity, fatigue, GI effects. Specific safety profile for selective TIPARP inhibitors remains unclear due to lack of clinical data.Potential concern exists regarding interference with normal cellular stress responses and transcriptional regulation if inhibited broadly.
06

Interacting drugs

No widely approved drugs specifically targeting TIPARP as of now
07

Biomarkers

No established biomarkers for patient selection or efficacy monitoring specific for TIPARP at this time.

Beyond the preview

Go deeper on TCDD-inducible poly(ADP-ribose) polymerase (TIPARP).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on TCDD-inducible poly(ADP-ribose) polymerase (TIPARP).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call